Clinical Data Suggest Decreased Bleeding Risk in People With Severe
Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposium
of Thrombosis and Haemostasis

GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- Baxter
Healthcare Corporation today announced the presentation of findings
from the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)
study program database showing a statistically significant
relationship between the duration of time spent with factor VIII
blood levels below one international unit per deciliter (1 IU/dL,
one percent of normal factor VIII level) and an increase in the
annual bleed rate in people with hemophilia A. The findings from
ADAPT suggest that maintaining trough levels above 1 IU/dL with
prophylactic therapy may decrease the number of bleeding episodes,
particularly in children.

"Until now there has been insufficient clinical evidence to
demonstrate that factor VIII levels less than 1 IU/dL are
associated with increased bleeding in patients receiving
prophylaxis for the management of hemophilia A," said Peter W.
Collins M.D., FRCP, FRCPath, Department of Haematology, University
Hospital of Wales, Cardiff, U.K.

"These results suggest that decreasing the amount of time a
patient spends with a factor VIII less than 1 IU/dL will reduce the
number of bleeds. This can be achieved in part by improving
adherence to prescribed prophylaxis, while measurement of trough
factor VIII levels in some patients may help individual tailoring
of factor VIII dosing regimens."

Dr. Collins presented data from the ADAPT group showing an
analysis of 48 children (one to six years of age) and 100
adolescents and adults (10 to 65 years of age) with severe
hemophilia A and factor VIII levels less than 1 IU/dL who
participated in ADVATE clinical trials. All participants were
initially evaluated in a 48-hour pharmacokinetic study to measure
their rate of clearance of ADVATE prior to initiation of
prophylactic therapy. The 10 to 65 years old group was treated for
75 exposure days on a fixed prophylactic regimen of 25-40 IU/kg 3-4
times a week irrespective of bleeding. Prophylaxis could be
modified by the physician (or investigator) for the one to six year
old group.

By analyzing individual pharmacokinetic data and doses infused,
Collins and coauthors were able to estimate the median number of
hours per week spent below the 1 IU/dL trough level for each
population, 19.7 hours and 16.5 hours for the one to six year old
and 10 to 65 years old groups respectively. Subsequent comparison
with bleed frequency for each group found that in the one to six
years of age group the time below 1 IU/dL while on prophylaxis was
associated with increased incidence of traumatic and spontaneous
total bleeds (p<0.0001). Similarly in subjects that remained on
a fixed prophylactic regimen in the 10 to 65 years age group, the
duration of time below 1IU/dL was associated with increased total
and joint bleeds (p<0.02).

"ADAPT continues to generate important information relating
treatment with outcomes for people with hemophilia A," said Bruce
Ewenstein, M.D., Ph.D., global medical director for hemophilia
therapies at Baxter. "These data from the ADVATE clinical program
have provided valuable insight into the potential role of
maintaining trough levels above 1 IU/dL to reduce the risk of
breakthrough bleeding."

Additionally, a poster presentation of data from ADAPT, results
showed that bleeding patterns in people with severe hemophilia
using standard prophylaxis therapy vary according to age groups.
For both adolescents and adults, joint bleeds were more likely to
occur in the summer, possibly due to increased physical activity.
Furthermore, in patients on a Monday-Wednesday- Friday dosing
schedule, a greater number of joint bleeds occurred on Sundays,
reaching statistical significance in adults (18 to 65 years of
age). The results support the concept of individual tailoring of
prophylactic regimens according to activity and bleeding
patterns.

About Hemophilia A

People with hemophilia A do not produce adequate amounts of
factor VIII, which is necessary for blood to effectively clot. If
untreated, patients with severe hemophilia A have a greatly reduced
life expectancy. According to the World Health Organization, more
than 400,000 people in the world have hemophilia, corresponding to
a prevalence of 15 to 20 in every 100,000 males born worldwide.

About ADAPT

The ADAPT (Analysis of Data from ADVATE Prospective Trials)
research program was initiated to further investigate and explore
the expanding ADVATE clinical study program database for additional
insight into general hemophilia medical research and practice
issues beyond the main goals of the Investigational New Drug (IND)
research program. ADAPT research goals include examining the
reliability and reproducibility of certain pharmacokinetic (PK)
measurements across a broad population of subjects. Such PK data
may be important to clinical development and evaluation of new
therapeutics, as well as for the prediction of relationships to
clinical outcomes and their utility in optimizing the routine
clinical management of hemophilia A. These studies may offer
guidance for designing individualized dosing regimens based on
patient PK profiles, which may allow for less frequent infusion
requirements or improved treatment outcomes.

It is important to note that prophylaxis is not an approved
therapy regimen in some countries, including the United States.
On-demand is the approved dosage regimen for most factor VIII
therapies in the United States.

About ADVATE

ADVATE is currently approved for use in the United States,
Australia, Japan and Europe.

ADVATE is indicated in hemophilia A (classical hemophilia) for
the prevention and control of bleeding episodes. ADVATE is also
indicated in the perioperative management of patients with
hemophilia A. ADVATE is not indicated for the treatment of von
Willebrand's disease. Infused directly into the bloodstream, ADVATE
works by temporarily raising the level of factor VIII in the blood,
thus allowing the body's blood clotting process to properly
function. ADVATE is the only recombinant factor VIII therapy
processed without blood or blood additives, including human albumin
or other plasma protein additives.

ADVATE should be administered cautiously in patients with
previous hypersensitivity to constituents of factor VIII
preparations or known sensitivity to mouse or hamster proteins.

The most common related adverse reactions observed during the
ADVATE clinical studies include: strange taste in mouth, headache,
dizziness and flushing. The formation of inhibitors has been
observed with all factor VIII concentrates, including ADVATE.

Patients and caregivers in the United States can obtain more
information on ADVATE, including full Prescribing Information, at
http://www.ADVATE.com. European
healthcare professionals can obtain information at http://www.emea.europa.eu

About Baxter

Baxter Healthcare Corporation is the principal U.S. operating
subsidiary of Baxter International Inc. . Baxter International
Inc., through its subsidiaries, assists healthcare professionals
and their patients with the treatment of complex medical
conditions, including cancer, hemophilia, immune disorders, kidney
disease and trauma. The company applies its expertise in medical
devices, pharmaceuticals and biotechnology to make a meaningful
difference in patients' lives.

This release includes forward-looking statements with respect to
the use of factor VIII to decrease the number of bleeding episodes
experienced by patients with hemophilia A including the use of
prophylaxis therapy. The statements are based on assumptions about
many important factors including the following, which could cause
actual results to differ materially from those in the
forward-looking statements: satisfaction of regulatory and other
requirements for the timely enrollment and commencement of
additional clinical studies; additional clinical results
demonstrating the safety and efficacy of the therapies; market
acceptance of such therapies; and other risks identified in the
company's most recent filing on Form 10-K and other SEC filings,
all of which are available on the company's web site. The company
does not undertake to update its forward-looking statements.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.